You have access
Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial
KEIICHIRO MIYAJIMA, TAKAFUMI YANAGISAWA, HIROTAKA SUZUKI, WATARU FUKUOKAYA, KEIGO SAKANAKA, KOKI OBAYASHI, JUN MIKI and TAKAHIRO KIMURA
Anticancer Research April 2023, 43 (4) 1611-1621; DOI: https://doi.org/10.21873/anticanres.16311
